The purpose of this post is to introduce my most recent column over at theHeart.org | Medscape Cardiology in which I address recent concerns about the drug rivaroxaban (Xarelto). — In 2014, Rivaroxaban (Xarelto) was the most prescribed new oral anticoagulant (NOAC). Millions of patients have atrial fibrillation, so it’s fair to call it a […]
Tag: Rivaroxaban
You may have heard that the new blood thinner, rivaroxaban (Xarelto) made news at the recent ACC meeting in Chicago. The Einstein PE trial showed rivaroxaban equivalent to standard therapy (enoxaparin followed by warfarin) in the treatment of pulmonary embolism (blood-clot in lungs). When the researchers looked at net clinical benefit, a measure that gives […]
Let’s get off cell biology and back to something I really know. Atrial fibrillation, AF ablation and blood thinners. There was an important study published today in the Journal of the American College of Cardiology concerning the use of the new blood thinner, dabigatran (Pradaxa), around the time of AF ablation. A very concise overview, […]
You can mark August 2011 as an amazing month for news in the treatment of atrial fibrillation (AF). In this post, I will attempt to share what I have learned about the two new blood-thinning drugs, apixaban and rivaroxaban–both Factor Xa inhibitors. (Disclaimer: this is not a book chapter, rather a blog post from a […]
The unrelenting epidemic of inactivity and excessive eating wreaks havoc on more than just the heart and blood vessels. Lugging around extra weight also breaks down the joints and back. For evidence, look no further than the waiting room of any orthopedist; the people waiting for joint replacements look the same as those waiting to […]